Huntsworth (LON:HNT) had its price objective hoisted by Berenberg Bank from GBX 135 ($1.72) to GBX 150 ($1.91) in a research report released on Wednesday. Berenberg Bank currently has a buy rating on the stock.

A number of other research analysts also recently weighed in on the company. Peel Hunt downgraded Huntsworth to an add rating and raised their price target for the company from GBX 115 ($1.47) to GBX 140 ($1.79) in a research note on Wednesday, July 18th. Numis Securities restated a buy rating on shares of Huntsworth in a research note on Tuesday, July 24th.

LON:HNT opened at GBX 122 ($1.56) on Wednesday. Huntsworth has a 52-week low of GBX 40 ($0.51) and a 52-week high of GBX 95 ($1.21).

Huntsworth (LON:HNT) last posted its quarterly earnings results on Tuesday, July 24th. The company reported GBX 2.60 ($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of GBX 2.80 ($0.04) by GBX (0.20) ($0.00). Huntsworth had a net margin of 5.63% and a return on equity of 6.97%.

The business also recently declared a dividend, which will be paid on Tuesday, November 6th. Shareholders of record on Thursday, September 27th will be paid a GBX 0.70 ($0.01) dividend. The ex-dividend date is Thursday, September 27th. This represents a yield of 0.57%.

About Huntsworth

Huntsworth plc operates as a healthcare communications and public relations company in the United States, United Kingdom, rest of Europe, Asia, and the Middle East and Africa. It operates through four divisions: Huntsworth Health, Red Consultancy, Grayling, and Citigate Dewe Rogerson (CDR). The Huntsworth Health division offers an integrated suite of communications services for the science, health, and wellbeing industries.

Recommended Story: Stock Symbol

Receive News & Ratings for Huntsworth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Huntsworth and related companies with's FREE daily email newsletter.